Ipsen (IPN.PA) and Inspiration Biopharmaceuticals Complete Sale of Haemophilia Assets
3/21/2013 7:38:09 AM
More...
|
Ipsen (IPN.PA) and Inspiration Biopharmaceuticals Announce Closing of the IB1001 Sale to Cangene Corporation (CC:CNJ)
2/20/2013 10:31:59 AM
More...
|
Celtic Pharma Welcomes the Results of the Sale Process of Inspiration Biopharmaceuticals' Hemophilia Assets to Cangene Corporation (CC:CNJ)
2/7/2013 9:47:32 AM
More...
|
Baxter International, Inc. (BAX) Grabs Deal Worth $700 Million From Ipsen (IPN.PA) and Bankrupt Inspiration Biopharmaceuticals
1/24/2013 7:13:46 AM
More...
|
Inspiration Biopharmaceuticals Highlights Positive Interim Data on Its Two Lead Investigational Product Candidates: Recombinant Porcine FVIII (OBI-1) and Recombinant Factor IX (IB1001)
12/13/2012 9:33:15 AM
More...
|
Ipsen (IPN.PA) and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation From FDA for Acquired Hemophilia A
11/20/2012 9:01:51 AM
More...
|
Inspiration Biopharmaceuticals Files for Chapter 11
10/31/2012 6:28:13 AM
More...
|
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
9/18/2012 10:26:09 AM
More...
|
Inspiration Biopharmaceuticals to Present at the UBS Global Life Sciences Conference
9/13/2012 12:34:13 PM
More...
|
Ipsen (IPN.PA) and Inspiration Biopharmaceuticals Renegotiate Strategic Partnership Agreement for Up to $50 Million
8/21/2012 8:01:49 AM
More...
|
|